Molecular characterization of squamous cell carcinoma of the anal canal

Samantha A. Armstrong[1], Rita Malley[1], Hongkun Wang[1], Heinz-Josef Lenz[2], David Arguello[3], Wafik S. El-Deiry[4], Joanne Xiu[3], Zoran Gatalica[3], Jimmy J. Hwang[5], Philip A. Philip[6], Anthony F. Shields[6], John L. Marshall[1], Mohamed E. Salem[5#], Benjamin A. Weinberg[1#^]

[1]Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA; [2]Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA; [3]Caris Life Sciences, Phoenix, AZ, USA; [4]Warren Alpert Medical School, Providence, RI, USA; [5]Department of Hematology/Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; [6]Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA

#These authors contributed equally to this work.

Contributions: (I) Conception and design: SA Armstrong, ME Salem, BA Weinberg; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: SA Weinberg, HJ Lenz, D Arguello, WS El-Deiry, J Xiu, Z Gatalica, JJ Hwang, PA Philip, AF Shields, JL Marshall, ME Salem, BA Weinberg; (V) Data analysis and interpretation: SA Armstrong, R Malley, H Wang, ME Salem, BA Weinberg; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Benjamin A. Weinberg, MD. Associate Professor of Medicine, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd. NW, Washington, DC 20007, USA. Email: baw12@gunet.georgetown.edu.

Background: Squamous cell carcinoma of the anal canal (SCCA) is an uncommon malignancy with limited therapeutic options. Nivolumab and pembrolizumab show promising results in patients with SCCA. Human papillomavirus (HPV)-negative tumors are frequently *TP53*-mutated (*TP53*-MT) and often resistant to therapy.

Methods: We present a large molecularly-profiled cohort of SCCA, exploring the underlying biology of SCCA, differences between *TP53*-wild type (*TP53*-WT) and *TP53*-MT tumors, and differences between local and metastatic tumors. SCCA specimens (n=311) underwent multiplatform testing with immunohistochemistry (IHC), in situ hybridization (ISH) and next-generation sequencing (NGS). Tumor mutational burden (TMB) was calculated using only somatic nonsynonymous missense mutations. Chi-square testing was used for comparative analyses.

Results: The most frequently mutated genes included *PIK3CA* (28.1%), *KMT2D* (19.5%), *FBXW7* (12%), *TP53* (12%) and *PTEN* (10.8%). The expression of PD-1 was seen in 68.8% and PD-L1 in 40.5% of tumors. High TMB was present in 6.7% of specimens. HER2 IHC was positive in 0.9%, amplification by chromogenic in situ hybridization (CISH) was seen 1.3%, and mutations in *ERBB2* were present in 1.8% of tumors. The latter mutation has not been previously described in SCCA. When compared with *TP53*-WT tumors, *TP53*-MT tumors had higher rates of *CDKN2A*, *EWSR1*, *JAK1*, *FGFR1* and *BRAF* mutations. PD-1 and PD-L1 expression were similar, and high TMB did not correlate with PD-1 (P=0.50) or PD-L1 (P=0.52) expression.

Conclusions: Molecular profiling differences between *TP53*-MT and *TP53*-WT SCCA indicate different carcinogenic pathways which may influence response to therapy. Low frequency mutations in several druggable genes may provide therapeutic opportunities for patients with SCCA.

Keywords: Squamous cell carcinoma of the anal canal (SCCA); anal carcinoma; targeted therapy; genomic profiling

Introduction

Anal cancers are relatively rare, with an estimated 8,590 new cases in the US in 2020, although the incidence is rising (1). The most common histological subtype of anal cancer is squamous cell carcinoma of the anal canal (SCCA) (2). Although SCCA occurs more frequently in women than men, its incidence is rising in men who have sex with men and persons infected with HIV (3). Despite this, treatment for locoregional SCCA has not changed in many years and consists of the Nigro protocol, first described in 1974, of definitive concurrent chemoradiation with 5-fluorouracil (5-FU) and mitomycin-C, with surgery reserved for the salvage setting (4). A phase III EORTC study confirmed the use of combined modality therapy with chemoradiation (5-FU plus mitomycin-C), demonstrating improved local control and colostomy-free survival compared to radiation alone (5). Until recently, metastatic SCCA was treated with the same decades-old chemotherapy regimen of 5-FU plus cisplatin (6). This combination was recently challenged by carboplatin plus weekly paclitaxel in the phase II InterAACT trial (n=91), results at a median follow-up of 28.6 months revealed that carboplatin plus paclitaxel had comparable response rates to 5-FU plus cisplatin; the overall response rate (ORR) was 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel versus 57% (95% CI, 39.4% to 73.7%) for cisplatin plus 5-FU, with reduced serious events (36% compared to 62% P=0.016) and improved progression-free survival [PFS, 8.1 months (95% CI, 6.6 to 8.8 months) versus 5.7 months (95% CI, 3.3 to 9.0 months)]. Median overall survival (OS) was 20 months (95% CI, 12.7 months to not reached) versus 12.3 months (95% CI, 9.2 to 17.7 months, HR 2.00, 95% CI, 1.15 to 3.47; P=0.014) (7). These data indicate carboplatin plus paclitaxel should be considered as a new standard of care. The persistence of these standards of care is in part due to the rarity of SCCA and the difficulty of completing large, randomized clinical trials. Moreover, patients with local disease have variable responses to chemoradiation. New insights into the molecular biology of SCCA reveal the underlying mechanisms of carcinogenesis and are changing the treatment paradigm.

Human papillomavirus (HPV) is involved in 85–88%

of SCCA (8). SCCA that is not related to HPV infection represents a small minority of cases. These cases are notoriously refractory to chemoradiation and frequently harbor *TP53* mutations (9). Deeper sequencing techniques on 392 HPV-PCR negative cervical cancer specimens, detected HPV in 43.1% of specimens (n=169) suggesting HPV as the oncogenic driver even if previously testing negative (10). Interestingly, many precursor lesions (anal intraepithelial neoplasia II/III) are also positive for HPV (especially HPV16), suggesting that HPV infection is an early event in potential oncogenesis; however, few of these precursor lesions will actually become malignant (11). It remains unclear why some precursor lesions progress while others do not, but immunosuppression (especially from HIV infection) plays a role via the evasion of HPV-specific CD4+ and CD8+ T cells (12,13). While HPV infection is often transient in immunocompetent individuals, HIV-positive patients often have a persistent HPV infection (9). The HPV viral genes *E6* and *E*7 contribute to oncogenic transformation. The E6 oncoprotein encoded by the HPV genome directly targets and inactivates the p53 protein, which usually functions as a tumor suppressor (14). Consequently, p53 is unable to induce apoptosis. The E7 oncoprotein effectively deregulates the cell-cycle; E7 forms complexes with the phosphorylated retinoblastoma protein (pRb), which is responsible for inhibiting transcriptional activity in the G1 phase of the cell cycle. Once complexed with E7, pRb is degraded, leading to progression of the cell through the S phase (15). Multiple other signaling pathways have been implicated in SCCA carcinogenesis, including epidermal growth factor receptor (EGFR), PI3K/AKT/mTOR, VEGF, hedgehog and Bcl-2 (15). Given the few treatment options for metastatic SCCA, knowledge of the activity of these pathways in individual tumors is vital to effective therapeutic selection.

A previous study of 199 recurrent or metastatic SCCA tumors was notable for frequent mutations in *PIK3CA* (33%) and *TP53* (15%). The tumors also had high immunohistochemistry (IHC) expression of EGFR (89%), TOP2A (85%), TOPO1 (67%) and low ERCC1 (49%), potentially conferring sensitivity to anti-EGFR antibodies, anthracyclines, irinotecan and platinum-based chemotherapies, respectively (16). Few tumors in this study

Table 1 Patient demographics

Parameter	Number
Total cases (n)	311
Age (years)	
Median age	61
Interquartile range	31–89
Gender, n (%)	
Female	225 (72.3)
Male	86 (27.7)
Location of primary tumor, n (%)	
Anus	117 (56.9)
Anal canal	92 (29.6)
Anorectum	16 (5.1)
Overlapping lesion of rectum, anus, anal canal	10 (3.2)
Rectum	7 (2.3)
Anorectal junction	6 (1.9)
Skin of anus	1 (0.3)
Perianal skin	1 (0.3)
Cloacagenic zone	1 (0.3)
Specimen site, n (%)	
Local	210 (67.5)
Distant metastasis	101 (32.5)

were tested for PD-1 or PD-L1, and PD-L1 expression is known to correlate with a worse prognosis in SCCA (17). Another study preformed comprehensive genomic profiling on 574 SCCA tumors to analyze the prevalence as well as mutational profiling details of tumor suppressor gene *CYLD* (18). *CYLD* mutations were seen in 13% of patients, and correlated with lower tumor mutational burden (TMB) and less alterations in *PIK3CA*. Additional comprehensive molecular profiling of SCCA are necessary to establish clinically useful biomarkers.

We sought to expand on this work through several avenues. First, we analyzed a large known cohort of molecularly-profiled SCCA. Second, by understanding the differences between profiles of primary and metastatic SCCA, pathways affecting metastasis can be identified. Third, there is recent data evaluating the molecular characteristics of the difference between *TP53*-WT versus *TP53*-MT tumors and our cohort adds to this growing field

(19,20). Thus, continued knowledge expansion of molecular pathways that confer this resistance to standard therapy would help guide the selection of alternative treatments. Finally, the exploding field of immunotherapy holds particular promise in metastatic SCCA. Because SCCA tends to flourish in an immunosuppressed environment, there is significant hope that checkpoint inhibition can be utilized to harness the immune system in attacking SCCA.

In this study, we aimed to establish the true prevalence of PD-1 and PD-L1 expression in a larger repository of SCCA tumors. In addition, we sought to analyze the mutational burden in SCCA tumors because a higher mutational burden may lead to greater diversity in neoantigens and increase the likelihood of an effective immune response (21). Mutational burden has proven to be a useful biomarker for efficacy of immunotherapy in non-small cell lung cancer, urothelial cancer, melanoma and mismatch repair (MMR)-deficient tumors (22-25). We present the following article in accordance with the MDAR reporting checklist (available at https://dx.doi.org/10.21037/jgo-20-610).

Methods

A multi-institutional database was searched to identify patients diagnosed with SCCA from January 1, 2015, through March 31, 2019. All patient data were deidentified, negating the need for patient informed consent. Each archived formalin-fixed, paraffin-embedded tumor sample or newly obtained biopsy sample was assessed by the Caris Life Sciences (Phoenix, AZ, USA) multiplatform profiling service. Tumor samples were accompanied by limited patient demographic and clinical information, and this is shown in *Table 1*.

Molecular analysis

All 311 SCCA specimens underwent multiplatform testing with the test selection based on the primary oncologist's recommendations. Testing included protein expression through IHC assay (n=302), gene amplification through chromogenic *in situ* hybridization (CISH, n=90), copy number alteration (CNA, n=215), fragment analysis (FA, n=15), fusion analysis via RNA sequencing (n=50), transcriptome sequencing (n=10) and next-generation sequencing [NGS, hot spot NGS (n=64) and Illumina NextSeq, 592 gene, NGS (n=226)]. TMB (n=209) was calculated using only somatic nonsynonymous missense mutations, and TMB-high was defined as ≥17 mutations (26).

```
                    ┌─────────────────────┐
                    │   SCCA Specimens     │
                    │      N=311           │
                    └─────────────────────┘
                              │
                              ▼
                    ┌─────────────────────┐
                    │   Specimen site      │
                    │   Local: N=210       │
                    │ Distant Metastasis: N=101 │
                    └─────────────────────┘
                              │
                              ▼
```

Testing
IHC N=15
NGS 592 N=1
CISH/IHC N=5
Fusion N=1
CISH/NGS Hot Spot N=1
NGS Hot Spot/IHC N=6
CNA/NGS 592 N=4
IHC/NGS 592 N=9
CISH/NGS Hot Spot/IHC N=56
CISH/IHC/NGS 592 N=1
NGS Hot Spot/IHC/Fusion N=1
IHC/CNA/NGS 592 N=143
IHC/CNA/NGS 592/Fusion N=12
CISH/IHC/CNA/NGS 592 N=15
CISH/CNA/NGS 592/Fusion N=1
CISH/NGS 592/Transcriptome N=1
IHC/CNA/NGS 592/FA N=12
IHC/CNA/NGS 592/Fusion/FA N=1
IHC/CNA/NGS 592/Fusion N=10
CISH/IHC/CNA/NGS 592/Fusion N=10
IHC/CNA/NGS 592/Transcriptome N=4
CISH/IHC/CNA/NGS 592/Fusion/FA N=1
IHC/CNA/NGS 592/Fusion/FA N=1

Figure 1 Specimen testing demographics. SCCA, squamous cell carcinoma of the anal canal; IHC, immunohistochemistry; NGS, next-generation sequencing; CISH, chromogenic in situ hybridization; CNA, copy number alteration; FA, fragment analysis.

Details of the samples' testing are shown in *Figure 1*.

IHC was performed on full formalin-fixed paraffin-embedded (FFPE) sections of glass slides, using automated staining techniques, per the manufacturer's instructions, and were optimized and validated per CLIA/CAO and ISO requirements. Staining was scored for intensity (0, no staining; 1+, weak staining; 2+, moderate staining; 3+, strong staining) and staining percentage (0–100%). Results were categorized as positive or negative by defined thresholds specific to each marker based on published clinical literature that associates biomarker status with patient responses to therapeutic agents. A board-certified

pathologist evaluated all IHC results independently. The primary antibody used against PD-L1 was SP142 (Spring Biosciences, Pleasanton, CA, USA). The staining was regarded as positive if its intensity on the membrane of the tumor cells was ≥2+ and the percentage of positively stained cells was >5%. The primary antibody used for PD-1 was MRQ-22 (Ventana) and staining was scored as positive if the number of PD-1+ TIL was >1 cell per high-power field. PD-1 TIL density was evaluated using a hotspot approach. The whole tumor sample was reviewed at a low power (4× objective), and the areas of highest density of TIL in direct contact with malignant cells of the tumor at 400× visual field (40× objective × 10× ocular) were enumerated.

Statistical analysis

The frequency of the protein expression, mutation and amplification data was compared between tumor samples that were *TP53*-WT *vs*. *TP53*-MT and primary *vs*. metastatic via either Chi-square tests or Fisher's exact tests when appropriate. SAS software version 9.4 (SAS Ins., Cary, NC, USA) was used for the analysis. P values <0.05 were considered statistically siginificant.

Ethical statement

Informed consent was not required for this study; these analyses were conducted using de-identified patient data obtained from Caris Life Sciences (Phoenix, AZ, USA) database. It was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Results

Baseline patient characteristics

We performed an analysis of 311 SCCA cases. The median patient age was 61 years (interquartile range, 31–89 years). The majority of patients (72.3%) were female, and specimens were examined from both primary and metastatic sites (67.5% and 32.5%, respectively), with the most common metastatic site being the liver (51.5%, n=52). Local specimen lesions include the anus, anal canal, anorectum, overlapping lesion of rectum/anus/anal canal, rectum, anorectal junction, skin of anus, perianal skin, cloacogenic zone, vagina/labia, urethra, skin of thigh, gluteal skin and inguinal lymph node. Distant metastatic specimen sites include liver, small bowel, omental, ovary,

brain, paraspinal, lung and pleural lesions as well as neck, cervical, supraclavicular, periaortic, paratracheal, subcarinal, scalene and retroperitoneal lymph nodes. *Table 1* provides the details of the patient demographic characteristics.

Recurrent mutation and biomarker incidence

Recurrent mutations were seen in 82 genes (*Table 2*). In summary, the most frequently mutated genes included *PIK3CA* (28.1%), *KMT2D* (19.5%), *FBXW7* (12%), *TP53* (12%) and *PTEN* (10.8%). Of the 220 tumors subjected to Illumina NextSeq (592 gene) testing, the most common mutations were *PIK3CA* (28.1%), *KMT2D* (19.5%), *KMT2C* (16.2%), *TP53* (12.0%), *PTEN* (10.8%), *FBXW7* (10.3%), *ARID1A* (4.8%), *ATRX* (4.1%), *APC* (3.8%) and *NOTCH1* (3.4%). IHC analysis showed frequent expression of EGFR (97.7%) and PTEN (68.1%). MMR deficiency frequency tested by IHC of MLH1, PMS2, MSH2 and MSH6 was 1.1%. Expression of PD-1 was seen in 68.8% (44/64) of tumors, and PD-L1 was seen in 40.5% (119/294). HER2 IHC was positive in 0.9% (1/106) of samples, and amplification by CISH was seen 1.3% (1/78) of samples. Mutations in *ERBB2* were present in 1.8% (4/219) of samples.

TMB and microsatellite instability (MSI)

Mean TMB was 8.6 mutations per megabase. High TMB, as tested by NGS, was present in 6.7% of tumors (n=209). MSI-high tumors by FA and NGS were present in 6.7% (1/15), and 1.3% (2/156) of specimens, respectively.

Mutational differences between TP53-WT and TP53-MT

A comparison of *TP53*-MT to *TP53*-WT samples is summarized in *Table 3*. The incidence rates of statistically non-significant mutations and biomarkers are summarized in Table S1. *CDKN2A* mutations, known to encode both p16 (INK4a) and p14 (ARF) genes, were exclusively seen in *TP53*-MT samples (6/25). Additional mutations seen only in *TP53*-MT samples were *BRAF* (2/25, NGS), *EWSR1* (1/24, CNA), *JAK1* (1/25, NGS) and *FGFR1* (2/24, CNA). When comparing biomarkers for immunotherapy, they were slightly less prevalent in *TP53*-MT compared to *TP53*-WT samples, although this difference was not statistically significant: IHC for PD-1, 50% (2/4) *vs.* 70% (42/60), P=0.583; IHC for PD-L1, 32.1% (9/28) *vs.* 41.4%

(110/266), P=0.345; NGS for MSI, 0% (0/25) *vs.* 1.53% (2/131); and NGS for FA, 0% (0/0) *vs.* 6.67% (1/15), P=1.000. All HER2-positive samples were from *TP53*-WT. When testing for *APC*, *TP53*-MT samples had a significantly higher incidence of *APC* than *TP53*-WT samples by NGS (20%, 5/25 compared to 1.6%, 3/187, P<0.001) and by NGS hotspot (33.33%, 1/3 compared to 0%, 0/59, P=0.048). *NOTCH1* incidence was also significantly higher in *TP53*-MT (12%, 3/25) than *TP53*-WT (2.23%, 4/179) with P=0.04 for NGS. The incidence of *CALR* by CNA was significantly higher in *TP53*-MT (8.33%, 2/24) compared to *TP53*-WT (0.55%, 1/181) tumors, P=0.037. *FGFR1* incidence was significantly higher in *TP53*-MT (8.33%, 2/24) than in *TP53*-WT tumors (0%, 0/185), P=0.013, and *ZNF703* incidence was higher in *TP53*-MT (8.33%, 2/24) compared to *TP53*-WT samples (0.59%, 1/170), P=0.041. *PIK3CA* incidence by NGS was significantly higher in *TP53*-WT (30.6%, 60/196) compared to *TP53*-MT samples (8%, 2/25), P=0.018.

Mutational differences between local and metastatic lesions

The analysis of both local and metastatic lesions is summarized in *Table 4*, with *Figure 2* illustrating the statistically significant differences in incidence rates between local and metastatic tumor samples. The incidence rates of statistically non-significant mutations and biomarkers are summarized in Table S2. Local tumors showed higher incidence of *PD-1* 80.9% (38/47 IHC) compared to 35.3% (6/17), P<0.001 in metastatic lesions. Local tumors also showed a higher incidence of *PTEN* 13.8% (19/138 NGS) compared to 4.5% (3/66 NGS) in metastatic lesions, P=0.047. Metastatic lesions had significantly greater incidence of *FGFR3* mutations, 6.8% (5/73 NGS) compared to 0% (0/141) in local tumors, P=0.004. All HER2-positive samples were from metastatic lesions.

Discussion

Although SCCA is a rare malignancy, its incidence and morbidity are increasing in the United States. Here we report an extensive comprehensive genomic profiling with NGS and gene expression profiling for patients with SCCA. Several tumor suppressor genes and oncogenes were newly identified in our population of SCCA.

Within this study, we were unable to identify HPV related cases by p16 overexpression given the lack of such

Table 2 Mutation and biomarker incidence

Name	Incidence (%)	Incidence ratio	Technique
MSH2	100	92/92	IHC
MSH6	100	90/90	IHC
MLH1	98.9	91/92	IHC
PMS2	98.9	87/88	IHC
EGFR	97.7	43/44	IHC
PD-1	68.8	44/64	IHC
PTEN	68.1	64/94	IHC
PD-L1	40.5	119/294	IHC
PIK3CA	28.1	62/221	NGS
PIK3CA	24.2	15/62	NGS hot spot
KMT2D	19.5	36/185	NGS
KMT2C	16.2	19/177	NGS
FBXW7	12.9	8/62	NGS hot spot
TP53	12.	25/208	NGS
PTEN	10.8	22/204	NGS
FBXW7	10.3	20/195	NGS
TMB	6.7	14/209	NGS
PIK3CA	5.4	11/205	CNA
TP53	5	3/60	NGS hot spot
ARID1A	4.8	4/84	NGS
ATRX	4.1	3/73	NGS
APC	3.8	8/212	NGS
NOTCH1	3.4	7/204	NGS
RB1	3.3	2/61	NGS hot spot
AKT1	3.2	2/62	NGS hot spot
KRAS	3.2	2/62	NGS hot spot
TRK A/B/C	3.1	2/64	IHC
BCL6	2.9	6/205	CNA
NFIB	2.9	6/205	CNA
PBRM1	2.9	6/206	NGS
EP300	2.9	5/174	NGS
CDKN2A	2.8	6/216	NGS
KRAS	2.7	6/221	NGS
FGF19	2.5	5/204	CNA
TFRC	2.4	5/205	CNA

Table 2 (*continued*)

Table 2 (*continued*)

Name	Incidence (%)	Incidence ratio	Technique
FGF4	2.4	5/208	CNA
FGF3	2.4	5/209	CNA
KDM5C	2.4	3/126	NGS
FGFR3	2.3	5/214	NGS
AKT1	2.3	5/218	NGS
BAP1	2.3	5/219	NGS
CYLD	2.1	4/191	NGS
RB1	2	4/197	NGS
PIK3R1	2	4/204	NGS
KLHL6	2	4/205	CNA
CCND1	1.9	4/210	CNA
BRCA2	1.9	4/215	NGS
MUTYH	1.8	4/217	NGS
ERBB2	1.8	4/219	NGS
ZNF703	1.5	3/203	CNA
CALR	1.5	3/205	CNA
ETV5	1.5	3/205	CNA
LPP	1.5	3/205	CNA
LYL1	1.5	3/205	CNA
PSIP1	1.5	3/205	CNA
SMAD2	1.5	3/205	CNA
EGFR	1.4	3/208	CNA
FH	1.4	3/215	NGS
CTNNB1	1.4	3/216	NGS
HRAS	1.4	3/221	NGS
MSI	1.3	2/156	NGS
CREBBP	1.1	2/188	NGS
NSD1	1	2/198	NGS
ARID2	1	2/200	NGS
MYB	1	2/202	CNA
ADGRA2	1	2/203	CNA
FANCG	1	2/204	CNA
PRRX1	1	2/204	CNA
KEAP1	1	2/205	CNA
KRAS	1	2/205	CNA

Table 2 (*continued*)

Table 2 (*continued*)

Name	Incidence (%)	Incidence ratio	Technique
MALT1	1	2/205	CNA
NSD3	1	2/205	CNA
SMAD4	1	2/205	CNA
SS18	1	2/205	CNA
FGFR1	1	2/209	CNA
MSH6	1	2/210	NGS
ERCC2	0.9	2/213	NGS
ATM	0.9	2/214	NGS
STK11	0.9	2/216	NGS
BRAF	0.9	2/217	NGS
ERBB3	0.9	2/218	NGS
BRCA1	0.9	2/219	NGS

IHC, immunohistochemistry; NGS, next-generation sequencing; CNA, copy number alteration.

testing's availability at the time of our cohort's analysis, other HPV driven malignancies such as head and neck cancer, cervical cancer and other gynecologic cancers utilize p16 overexpression as a confirmation for HPV infection as well as a prognostic marker related to PFS and OS [8–11]. The prognostic value of HPV-DNA and p16 expression in SCCA has also been explored, with results revealing that patients testing positively for both HPV-DNA and p16 overexpression have longer OS [18–19]. Newer unlike other gastrointestinal malignancies such as colon or pancreatic adenocarcinomas, SCCA rarely harbors *KRAS* mutations, with an incidence of 3% or less, which is confirmed in this comprehensive analysis (27,28). Similar to smaller studies, *PIK3CA* was the most common mutation identified. *PIK3CA* mutations are seen in approximately one-third of all specimens, frequently occurring in *TP53*-WT tumors (see *Figure 3*), suggesting that HPV may drive the accumulation of activating mutations in *PIK3CA*, which have been linked to higher risks of relapse (16,27-30). *PIK3CA* mutations have been identified in other HPV driven malignancies, including SCC of the head and neck (31). In addition, *MLL2/KMT2D* and *MLL3/KMT2C* are important in histone modification and are associated with oncogenesis as well as *TP53* expression in preclinical studies. Prior SCCA studies identified mutations in these genes (29,32,33). Our analysis revealed high rates of mutations in both epigenetic regulators *MLL2/KMT2D* (19.5%) and *MLL3/KMT2C* (16.2%), the majority of both mutations in *TP53*-WT specimens.

The tumor suppressor gene *TP53*, responsible for cell cycle regulation and apoptosis, is known to be overexpressed in SCCA. Many studies have seen a correlation between *TP53* mutations and worse locoregional control and reduced disease-free survival in patients with SCCA (34-37). One study (n=119) found 4% of SCCA expressed exon 5 *TP53* mutations (30). Another recent study (n=106) confirmed the correlation with HPV-negativity, p53 staining, and *TP53* mutation in SCCA are associated with inferior OS as well as reduced recurrence-free survival (19). Our study discovered *TP53* mutations in 12% of NGS samples (25/208) and 5% of NGS hot spot samples (3/60).

Rare mutations noted in this study include *HRAS*, found in 1.4% (3/221 NGS) of samples, all of which were in local *TP53*-WT specimens. *HRAS* was first noted in a smaller SCCA whole-exome sequencing cohort, along with *ARID1A* mutations, and were felt to be driver mutations of SCCA (38). *ARID1A* was prevalent in 4.8% (4/84 NGS) of our study specimens, all of which were *TP53*-WT, mostly localized tumors.

Potentially targetable mutations

Outside of immunotherapy, there are currently no clinically established biological markers to guide therapy for patients with SCCA. *Table 5* reviews potentially targetable mutations identified in this analysis.

PI3KCA

As noted above, *PIK3CA* was the most common mutation in this collection of SCCA samples, with an incidence of 28.1% (62/221) by NGS, and 24.2% (15/62) by NGS hot spot. PI3K and AKT are located downstream of the EGFR receptor. Following the binding of EGFR to its receptor and subsequent activation of PI3K and AKT, the cell signals to survive and proliferate. Mutations in *PIK3CA*, a portion of the PI3K kinase, result in constitutive PI3K activity, subsequent activation of AKT, and downstream oncogenic activity (29,30). In one PDX mouse model of SCCA, there was no did response to treatment with a PI3K inhibitor, suggesting that the high *PIK3CA* mutation rate and abnormally high PI3K activity plays an important role in anal carcinogenesis (29,38). The high prevalence

Table 3 Incidence rates of statistically significant mutations and biomarkers in *TP53*-MT (n=28) tumors versus *TP53*-WT (n=238)

Alteration	Test	*TP53*-MT (n=28) incidence (%)	*TP53*-MT incidence ratio	*TP53*-WT (n=238) incidence (%)	*TP53*-WT incidence ratio	P value
Tumor suppressor genes						
CDKN2A	NGS	24	6/25	0	0/191	0.0000
Immune						
APC	NGS	20	5/25	1.6	3/187	0.0007
APC	NGS hot spot	33.33	1/3	0	0/59	0.0484
RAS/RAF/MEK						
BRAF	NGS	8	2/25	0	0/192	0.0128
PI3K related kinases						
PIK3CA	NGS	8	2/25	30.6	60/196	0.0178
Other						
NOTCH1	NGS	12	3/25	2.23	4/179	0.0410
CAL-R	CNA	8.33	2/24	0.55	1/181	0.0367
FGFR1	CNA	8.33	2/24	0	0/185	0.0127
ZNF703	CNA	8.33	2/24	0.55	1/170	0.0409

TP53-MT, *TP53*-mutated; *TP53*-WT, *TP53*-wild type; NGS, next-generation sequencing; CNA, copy number alteration.

Table 4 Incidence rates of statistically significant mutations and biomarkers in local versus metastatic locations

Alteration	Test	Metastatic incidence (%)	Metastatic incidence ratio	Local incidence (%)	Local incidence ratio	P value
Immune						
PD-1	IHC	35.29	6/17	80.85	38/47	0.0005
SMAD pathway						
SMAD2	CNA	4.35	3/69	0	0/137	0.0365
PI3K related kinases						
PTEN	NGS	4.55	3/66	13.77	19/138	0.0470
Other						
FGFR3	NGS	6.85	5/73	0	0/141	0.0042

IHC, immunohistochemistry; CNA, copy number alteration; NGS, next-generation sequencing.

of PIK3CA mutations seen in this analysis invites further analysis of PI3K and mTOR inhibitors as potential therapeutic options.

EGFR

Overexpression of EGFR is believed to contribute to tumor development and unregulated cell proliferation and is seen in many epithelial cancers. Our IHC results showed that 97.7% of SCCA samples express EGFR (43/44), although the rate of EGFR mutations, by CNA, is low at 1.4% (3/208). No EGFR mutations were found in 219 NGS or 62 NGS hot spot samples. Similar combinations of high rates of EGFR expression with low mutational rates have been seen in smaller SCCA studies (39-42). Cetuximab is an IgG1 chimeric monoclonal antibody against EGFR that is utilized in other gastrointestinal malignancies when no downstream K-RAS/N-RAS/BRAF mutations are present.

Figure 2 Incidence of mutations in PI3K related kinases in local and metastatic cases of SCCA. *, P<0.05; **, P<0.01; ***, P<0.001. SCCA, squamous cell carcinoma of the anal canal; NGS, next-generation sequencing; CNA, copy number alteration; IHC, immunohistochemistry.


Figure 3 Incidence of mutations in *TP53*-MT (n=28) tumors and *TP53*-WT (n=238). *, P<0.05. CNA, copy number alteration; NGS, next-generation sequencing; *TP53*-MT, *TP53*-mutated; *TP53*-WT, *TP53*-wild type.

The use of cetuximab in patients with SCCA has been studied without success. The phase II ECOG 3,205 and AMC0 45 trials both evaluated the addition of cetuximab to standard frontline 5-FU plus cisplatin concurrent with radiation (43,44). Unfortunately, substantial patient toxicity was seen with added cetuximab; 26–32% of patients experienced grade 4 toxicities (compared to a historic rate of 20% in the RTOG 98-11 trial) (45). Similar studies

utilizing cetuximab to treat SCCA also revealed significant toxicities (46-48). However, it is possible that cetuximab may be useful in the *PIK3CA* wild-type subgroup.

HER2

In the same tyrosine kinase receptor family as EGFR is HER2/ERBB2, ERBB3 and ERBB4. HER2 expression has

Table 5 Potentially targetable mutations outside of immunotherapy

Potentially targetable mutation/test	Treatment	Incidence
DDR pathways	Synthetic lethality with agents combined with a PARPi	
BRCA 1/NGS		2/219 (0.9%)
BRCA 2/NGS		4/215 (1.9%)
ATM/NGS		2/214 (0.9%)
ATRX/NGS		3/73 (4.1%)
PTEN/IHC		64/94 (68.1%)
PIK3CA		
PIK3CA/NGS		62/221 (28.1%)
PIK3CA/NGS hot spot		15/62 (24.2%)
PIK3CA/CNA		11/205 (5.4%)
BRAF	BRAF/MEK inhibitors	
BRAF NGS		2/217 (0.9 %)
HER2	Targeted HER2 agents	
ERBB2 NGS		4/219 (1.8%)
HER2/IHC		1/106 (0.9%)
HER2/CISH		1/78 (1.3%)
EGFR	EGFR inhibitors	
EGFR/IHC		43/44 (97.7%)
EGFR/CNA		3/208 (1.4%)
FGFR	FGFR inhibitors	
FGFR3/NGS		5/214 (2.3%)
FGFR2/NGS		1/215 (0.05%)

DDR, DNA damage response; NGS, next-generation sequencing; IHC, immunohistochemistry; CNA, copy number alteration; EGFR, epidermal growth factor receptor; FGFR, Fibroblast growth factor receptor.

been well described and documented in many malignancies. It is prevalent in breast cancer and gastric cancer and seen less commonly in salivary, vaginal, bladder, endometrial, cervical and colorectal cancers (49-56). HER2 has emerged as a successful therapeutic target transforming outcomes for patients with breast and gastric cancers. The MY PATHWAY basket trial studied the efficacy of pertuzumab and trastuzumab in HER2-positive tumors, and responses were seen in 9 different tumor types, giving further indication that HER2 is an actionable mutation across many malignancies (57). Our molecular analysis is the first to identify HER2 expression and *ERBB2* mutations in SCCA. HER2 IHC was positive in 0.9%, amplification by CISH was seen 1.3%, and mutations in *ERBB2* were present in

1.8% of tumors from our population. These findings could lead to novel therapeutic options for this patient population, and the adoption of widespread tumor molecular profiling would allow patients to participate in clinical trials of molecularly-matched therapies.

BRAF

BRAF is located downstream of EGFR. The BRAF protein is a serine/threonine protein kinase responsible for regulating the MAPK/ERK signaling pathway during cell proliferation, differentiation, growth and apoptosis (58). Mutations in the *BRAF* gene result in downstream activation of the MAPK pathway via phosphorylation of

MEK and ERK. The most common type of *BRAF* mutation is the V600E missense mutation.

In this population of SCCA, the *BRAF* mutation rate was relatively low, with an overall incidence of 0.9% (n=2) by NGS. This is consistent with previous reports of SCCA mutational analyses, which found most SCCA to be *BRAF* wild-type on whole-exome sequencing (28,29).

FGFR

Fibroblast growth factor receptors (FGFRs) are a subset of tyrosine kinases unregulated in cancer cells leading to increased proliferation, angiogenesis and cell survival. FGFR inhibitors are approved in biliary and urothelial cancers with FGFR alterations and appear to have activity in other malignancies with FGFR alterations (59-61). Fusions for *FGFR2* and *FGFR3* were not identified in the 12 samples checked. *FGFR2* mutations were identified in 0.05% of samples (n=215) by NGS samples. *FGFR3* mutations had an incidence of 2.3% (n=214) by NGS. The incidence of FGFR mutations and fusions in SCCA is low, but warrants further investigation of efficacy with FGFR inhibitors as an innovative therapeutic strategy to overcome drug resistance in the disease.

Immunotherapy

PD-1 blockade with nivolumab or pembrolizumab has shown promising results in SCCA patients (13,62), and we highlight data on the prevalence of TMB, PD-1 and PD-L1 expression in a larger repository of SCCA tumors. PD-L1 expression was found to be high in SCCA, which is likely related to the immune response to HPV oncoproteins (62). A recently published study preformed PD-L1 staining on 62 SCCA tumors and found expression (CPS ≥1) in 32% of cases (19). Amongst those who were HPV-negative with PD-L1 expression, there was a trend toward shorter OS (9.8 *vs.* 40.6 months; P=0.064). The first trial to establish the therapeutic benefits of immunotherapy in SCCA was the phase II NCI9673 study. This trial investigated the efficacy of nivolumab (3 mg/kg every 2 weeks) in patients with unresectable/metastatic SCCA, who had progressed on prior chemotherapy. The results revealed an objective response rate of 24% and a disease control rate of 72%, including 2 complete and 7 partial responses (13). Thirty patients

underwent pretreatment cell-free DNA analysis which revealed mutations in *TP53* (n=8, 27%) and *PIK3CA* (n=7, 23%) (13). Median PFS was 4.1 months, and median OS was 11.5 months. Responders had a higher percentage of CD3+ and CD8$^+$ T cells and higher expression of granzyme-B, PD-1 and PD-L1 on tumor cells (13). Another study was the multicohort phase 1B KEYNOTE-028 trial for PD-L1 positive (≥1%) tumors, in which patients were treated with pembrolizumab at a dose of 10 mg/kg IV once every 2 weeks. Study investigators treated 24 patients with advanced SCCA and observed an ORR of 17% (95% CI, 5.0–37%) and a disease control rate of 58%. The median PFS was 3.0 months (95% CI, 1.7–7.3 months), with 6- and 12-month PFS rates of 31.6% and 19.7%, respectively (62). Results from these trials led to preferential selection of immunotherapy in the second-line for patients with advanced SCCA (63).

Cancers with high TMB, including melanoma and colorectal cancers, respond well to immune checkpoint inhibition, indicating that mutational load correlates with response to checkpoint inhibitors (62). Data suggest only a moderate mutation rate in SCCA, which is accordant with other HPV-associated cancers (13,62). Hence SCCA response to immune checkpoint inhibition is more likely related to an inflammatory tumor microenvironment than to TMB (13). Further evaluation of the efficacy of immune checkpoint inhibitors is ongoing in several clinical trials, as outlined in *Table 6*.

Limitations

Limitations of this study include the lack of broad HPV-DNA and p16 testing to correlate with HPV infection in the setting of SCCA and lack of clinical treatment and outcomes data to correlate with mutational analysis. The first is due to the lack of such testing's availability as well as lack of relevance in SCCA at the time of our population's diagnosis. Other limitations include lack of each patient clinical or pathologic staging, ability to obtain germline DNA testing and lack of details regarding specimen histopathologic findings.

Conclusions

In conclusion, we report on the largest comprehensive molecular profiling study of patient SCCA, which provides

Table 6 Review of ongoing clinical trials utilizing immunotherapy or targetable mutations

Clinical trial	Size (n)	Molecular target	Title	Status
NCT03233711	200	PD-1; PD-L1	A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer	Recruiting April 17, 2020
NCT02314169	137	PD-1; CTLA-4	A Multi-Institutional Phase II Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic SCCA	Recruiting April 10, 2020
NCT03074513	160	PD-L1	A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors	Recruiting June 13, 2019
NCT02919969	32	PD-L1; VEGF	A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Center	Recruiting July 25, 2019
NCT04287868	29	HPV vaccine; PDL1/ TGF-b; IL-12	Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies	Recuriting June 11, 2020

SCCA, squamous cell carcinoma of the anal canal; HPV, human papillomavirus.

insights into the pathogenesis of SCCA and identifies potential therapeutic targets.

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at https://dx.doi.org/10.21037/jgo-20-610

Peer Review File: Available at https://dx.doi.org/10.21037/jgo-20-610

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jgo-20-610). DA, JX, ZG are employed by Caris Life Sciences. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was not required. These analyses were conducted using de-identified patient data obtained from Caris Life Sciences database.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Williams GR, Talbot IC. Anal carcinoma--a histological review. Histopathology 1994;25:507-16.
3. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026-34.
4. Nigro ND, Vaitkevicius VK, Buroker T, et al. Combined therapy for cancer of the anal canal. Dis Colon Rectum 1981;24:73-5.
5. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J

Clin Oncol 1997;15:2040-9.

6. Faivre C, Rougier P, Ducreux M, et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 1999;86:861-5.

7. Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol 2020;38:2510-8.

8. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626-36.

9. Meulendijks D, Tomasoa NB, Dewit L, et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer 2015;112:1358-66.

10. Arroyo Mühr LS, Lagheden C, Lei J, et al. Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. Br J Cancer 2020;123:1790-5.

11. Hoots BE, Palefsky JM, Pimenta JM, et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375-83.

12. Gervaz P, Hirschel B, Morel P. Molecular biology of squamous cell carcinoma of the anus. Br J Surg 2006;93:531-8.

13. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446-53.

14. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.

15. Bernardi MP, Ngan SY, Michael M, et al. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol 2015;16:e611-21.

16. Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6:43594-604.

17. Gujja S, Williamson SK, Batra A, et al. Programmed cell death-ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of the anal canal (SCCAC). J Clin Oncol 2015;33 suppl:abstr 3523.

18. Williams EA, Montesion M, Sharaf R, et al. CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. Mod Pathol 2020;33:2614-25.

19. Zhu X, Jamshed S, Zou J, et al. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status. Mod Pathol 2021;34:1017-30.

20. Chung JH, Sanford E, Johnson A, et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol 2016;27:1336-41.

21. Qiu P, Pang L, Arreaza G, et al. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. Int J Mol Sci 2016;17:651.

22. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20.

23. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.

24. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.

25. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.

26. Stadler ZK, Battaglin F, Middha S, et al. Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. J Clin Oncol 2016;34:2141-7.

27. Cacheux W, Rouleau E, Briaux A, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114:1387-94.

28. Martin V, Zanellato E, Franzetti-Pellanda A, et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol 2014;29:513-21.

29. Morris V, Rao X, Pickering C, et al. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res

2436

Armstrong et al. Molecular characteristics of anal squamous cell carcinoma

2017;15:1542-50.

30. Patel H, Polanco-Echeverry G, Segditsas S, et al. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer 2007;121:2668-73.

31. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761-9.

32. Hu D, Gao X, Morgan MA, et al. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol 2013;33:4745-54.

33. Schneider R, Bannister AJ, Myers FA, et al. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol 2004;6:73-7.

34. Allal AS, Waelchli L, Bründler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003;9:6489-96.

35. Bonin SR, Pajak TF, Russell AH, et al. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer 1999;85:1226-33.

36. Ogunbiyi OA, Scholefield JH, Smith JH, et al. Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol 1993;46:507-12.

37. Wong CS, Tsao MS, Sharma V, et al. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1999;45:309-14.

38. Shin S, Park HC, Kim MS, et al. Whole-exome sequencing identified mutational profiles of squamous cell carcinomas of anus. Hum Pathol 2018;80:1-10.

39. Alvarez G, Perry A, Tan BR, et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006;19:942-9.

40. Hui YZ, Noffsinger AE, Miller MA, et al. Strong Epidermal Growth Factor Receptor Expression But Not HER2/neu Expression Correlates with Cell Proliferation in Anal Canal Carcinomas. Int J Surg Pathol 1999;7:193-203.

41. Lê LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 2005;124:20-3.

42. Paliga A, Onerheim R, Gologan A, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 2012;107:1864-8.

43. Garg MK, Zhao F, Sparano JA, et al. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 2017;35:718-26.

44. Sparano JA, Lee JY, Palefsky J, et al. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol 2017;35:727-33.

45. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-21.

46. Deutsch E, Lemanski C, Pignon JP, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013;24:2834-8.

47. Levy A, Azria D, Pignon JP, et al. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 2015;114:415-6.

48. Olivatto LO, Vieira FM, Pereira BV, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 2013;119:2973-80.

49. Khasraw M, Bell R. Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev Anticancer Ther 2012;12:1005-13.

50. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691-7.

51. Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014;40:770-80.

52. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 2013;17:85-99.

53. Diver EJ, Foster R, Rueda BR, et al. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist 2015;20:1058-68.

54. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015;28:1481-91.

55. Conradi LC, Styczen H, Sprenger T, et al. Frequency of

HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol 2013;37:522-31.

56. Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 2017;8:86356-68.

57. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol 2018;36:536-42.

58. Hussain MR, Baig M, Mohamoud HS, et al. BRAF gene: From human cancers to developmental syndromes. Saudi J Biol Sci 2015;22:359-73.

59. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019;381:338-48.

60. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84.

61. Chae YK, Hong F, Vaklavas C, et al. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol 2020;38:2407-17.

62. Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-41.

63. NCCN. NCCN Guidelines for Anal Cancer 2021. Available online: https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf

Table S1 Incidence rates of statistically non-significant mutations and biomarkers in *TP53*-MT (n=28) tumors versus *TP53*-WT (n=238)

Alteration	Test	*TP53*-MT (n=28) incidence (%)	*TP53*-MT incidence ratio	*TP53*-WT (n=238) incidence (%)	*TP53*-WT incidence ratio	P value
Tumor suppressor genes						
p16	IHC	0	0/0	100	1/1	
RB1	NGS	8	2/25	1.16	2/172	0.0792
RB1	NGS hot spot	33.33	1/3	1.72	1/58	0.0967
Immune						
PD-1	IHC	50	2/4	70	42/60	0.5831
PD-L1	IHC	32.1	9/28	41.35	110/266	0.3449
MSI	NGS	0	0/25	1.53	2/131	1.0000
MSI	FA	0	0/0	6.67	1/15	
TMB	NGS	0	0/25	7.6	14/184	0.3854
BCL-6	CNA	0	0/24	3.31	6/181	1.0000
EGFR						
EGFR	CNA	0	0/24	1.63	3/184	1.0000
EGFR	IHC	66.67	2/3	100	41/41	0.0682
HER2	CISH	0	0/28	2	1/50	1.0000
HER2	IHC	0	0/8	1.02	1/98	1.0000
ERBB3	NGS	4	1/25	0.52	1/193	0.2167
ERBB2	NGS	0	0/25	2.06	4/194	1.0000
Cyclins						
Cyclin D1	CNA	0	0/24	2.15	4/186	1.0000
Cyclin E	CNA	0	0/24	0.54	1/185	1.0000
DDR						
BRCA2	CNA	0	0/24	0.56	1/177	1.0000
BRCA2	NGS	4	1/25	1.57	3/190	0.3924
BRCA1	NGS	4	1/25	0.51	1/194	0.2157
ATRX	NGS	0	0/25	6.25	3/48	0.5466
ATM	NGS	0	0/25	1.05	2/189	1.0000
RAS/RAF/MEK						
KRAS	CNA	0	0/24	1.11	2/181	1.0000
KRAS	NGS	8	2/25	2.04	4/196	0.1389
KRAS	NGS hot spot	33.33	1/3	1.69	1/59	0.0952
HRAS	NGS	0	0/25	1.5	3/196	1.0000
FGFR3	NGS	0	0/25	2.64	5/189	1.0000
FGFR2	NGS	0	0/25	0.53	1/189	1.0000
SMAD pathway						
SMAD 4	NGS	0	0/25	0.515	1/194	1.0000
SMAD4	CNA	4.16	1/24	0.55	1/181	0.2210
SMAD2	CNA	4.16	1/24	1.1	2/181	0.3131

Table S1 (*continued*)

Table S1 (*continued*)

Alteration	Test	*TP53*-MT (n=28) incidence (%)	*TP53*-MT incidence ratio	*TP53*-WT (n=238) incidence (%)	*TP53*-WT incidence ratio	P value
PI3K related kinases						
TRK A/B/C	IHC	0	0/5	3.39	2/59	1.0000
PIK3CA	CNA	0	0/24	6.07	11/181	0.3689
PIK3CA	NGS hot spot	0	0/3	25.4	15/59	1.0000
PIK3R1	NGS	0	0/25	2.23	4/179	1.0000
AKT	NGS	0	0/25	2.59	5/193	1.0000
AKT	NGS hot spot	0	0/3	3.39	2/59	1.0000
MTOR	NGS	0	0/25	0.53	1/187	1.0000
CCND1	CNA	4.17	1/24	1.6	3/186	0.3869
PTEN	NGS	0	0/25	12.3	22/179	0.0826
PTEN	NGS hot spot	0	0/3	1.72	1/58	1.0000
PTEN	IHC	44.4	4/9	70.59	60/85	0.1385
MMR						
ARID1A	NGS	0	0/25	6.78	4/59	0.3128
ARID2	NGS	0	0/25	1.14	2/175	1.0000
MSH6	NGS	0	0/25	1.08	2/185	1.0000
MSH6	IHC	100	6/6	89.36	84/94	1.0000
MLH1	NGS	0	0/25	0.52	1/190	1.0000
MLH1	IHC	100	6/6	98.8	85/86	1.0000
MSH2	IHC	100	6/6	100	86/86	1.0000
Other						
MEN1	NGS	0	0/25	0.51	1/196	1.0000
KMT2D	NGS	4	1/25	21.87	35/160	0.0530
KMT2C	NGS	4	1/25	19.56	18/92	0.0710
FBXW7	NGS	0	0/25	11.76	20/170	0.0821
FBXW7	NGS hot spot	33.33	1/3	11.86	7/59	0.3442
PBRM1	NGS	8	2/25	2.2	4/181	0.1564
BAP1	NGS	4	1/25	2.06	4/194	0.4578
EWSR1	CNA	4.17	1/24	0	0/179	0.1182
FGF19	CNA	4.17	1/24	2.2	4/180	0.4687
FGF3	CNA	4.17	1/24	2.2	4/185	0.4600
FGF4	CNA	4.17	1/24	2.2	4/184	0.4617
KEAP1	CNA	4.17	1/24	0.55	1/181	0.2210
LYL1	CNA	4.17	1/24	1.1	2/181	0.3131
MALT1	CNA	4.17	1/24	0.55	1/181	0.2210
SS18	CNA	4.17	1/24	0.55	1/181	0.2210
JAK1	CNA	4	1/25	0	0/176	0.1244
ADGRA2	CNA	4.17	1/24	0.55	1/179	0.2230
FANCG	CNA	4.17	1/24	0.55	1/180	0.2220
NSD3	CNA	4.17	1/24	0.55	1/181	0.2210

TP53-MT, *TP53*-mutated; *TP53*-WT, *TP53*-wild type; IHC, immunohistochemistry; MSI, microsatellite instability; NGS, next-generation sequencing; FA, fragment analysis; TMB, tumor mutational burden; CNA, copy number alteration; EGFR, epidermal growth factor receptor; CISH, chromogenic in situ hybridization; DDR, DNA damage response; MMR, mismatch repair.

Table S2 Incidence rates of statistically non-significant mutations and biomarkers in local versus metastatic locations

Alteration	Test	Metastatic incidence (%)	Metastatic incidence ratio	Local incidence (%)	Local incidence ratio	P value
Tumor suppressor genes						
TP53	NGS & NGS hot spot	7.06	6/85	11.05	20/181	0.3068
TP53	NGS	7.04	5/71	14.60	20/137	0.1121
TP53	NGS hot spot	6.25	1/16	4.55	2/44	1.0000
p16	IHC	0	0/100	100	1/1	
RB1	NGS	1.61	1/62	2.22	3/135	1.0000
RB1	NGS hot spot	12.50	2/16	0.00	0/45	0.0656
CDKN2A	NGS	1.39	1/72	3.47	5/144	0.6661
Immune						
PD-L1	IHC	39.36	37/94	41.00	82/200	0.7895
MSI	NGS	0.00	0/53	1.94	2/103	0.5485
MSI	FA	0.00	0/7	12.50	1/8	1.0000
TMB	NGS	7.25	5/69	6.43	9/140	0.7776
BCL-6	CNA	5.80	4/69	1.47	2/136	0.1822
APC	NGS	4.23	3/71	3.55	5/141	1.0000
APC	NGS hot spot	6.25	1/16	0	0/46	0.2581
EGFR						
EGFR	CNA	1.47	1/68	1.43	2/140	1.0000
EGFR	IHC	90.91	10/11	100	33/33	0.2500
HER2	CISH	5.00	1/20	0	0/58	0.2564
HER2	IHC	3.03	1/33	0	0/73	0.3113
ERBB3	NGS	1.35	1/74	0.69	1/144	1.0000
ERBB2	NGS	1.37	1/73	2.05	3/146	1.0000
Cyclins						
Cyclin D1	CNA	1.47	1/68	2.26	3/133	1.0000
DDR						
BRCA 2	CNA	0	0/67	0.75	1/134	1.0000
BRCA2	NGS	0	0/70	2.76	4/145	0.3064
BRCA1	NGS	2.70	2/74	0.00	0/145	0.1132
ATRX	NGS	0	0/19	5.56	3/54	0.5629
ATM	NGS	2.90	2/69	0	0/145	0.1029
RAS/RAF/MEK						
KRAS	CNA	1.45	1/69	0.74	1/136	1.0000
KRAS	NGS	1.35	1/74	3.40	5/147	0.6663
KRAS	NGS hot spot	12.5	2/16	0.00	0/46	0.0635
HRAS	NGS	0	0/74	2.04	3/147	0.5525
BRAF	NGS	1.41	1/71	0.68	1/146	0.5483
SMAD pathway						
SMAD 4	NGS	0.00	0/73	0.68	1/146	1.0000
SMAD4	CNA	2.90	2/69	0	0/137	0.1111

Table S2 (*continued*)

Table S2 (*continued*)

Alteration	Test	Metastatic incidence (%)	Metastatic incidence ratio	Local incidence (%)	Local incidence ratio	P value
PI3K related kinases						
TRK A/B/C	IHC	0.00	0/16	4.17	2/48	1.0000
PIK3CA	CNA	8.70	6/69	3.65	5/137	0.1865
PIK3CA	NGS hot spot	37.50	6/16	19.57	9/46	0.1823
PIK3R1	NGS	2.94	2/68	1.47	2/136	0.6020
PIK3CA	NGS	29.73	22/74	27.21	40/147	0.6941
AKT	NGS	1.35	1/74	2.78	4/144	0.6640
AKT	NGS hot spot	6.25	1/16	2.17	1/46	0.4527
MTOR	NGS	0	0/70	0.70	1/142	1.0000
PTEN	NGS hot spot	0	0/16	2.22	1/45	1.0000
PTEN	IHC	61.54	16/26	70.59	48/68	0.3998
MMR						
ARID1A	NGS	4.00	1/25	5.08	3/59	1.0000
ARID2	NGS	0	0/66	1.49	2/134	1.0000
MSH6	NGS	1.43	1/70	0.71	1/140	1.0000
MSH6	IHC	100.00	21/21	100.00	69/69	
MLH1	NGS	0.00	0/72	0.70	1/143	1.0000
MLH1	IHC	100.00	21/21	98.59	70/71	1.0000
MSH2	IHC	100.00	21/21	100.00	71/71	
Other						
MEN1	NGS	1.35	1/74	0	0/147	0.3348
KMT2D	NGS	18.03	11/61	20.16	25/124	0.7310
KMT2C	NGS	16.13	5/31	16.28	14/86	0.9845
FGFR2	NGS	0	0/71	0.70	1/143	1.0000
FBXW7	NGS	8.06	5/62	11.28	15/133	0.4909
FBXW7	NGS hot spot	25.00	4/16	8.70	4/46	0.1872
NOTCH1	NGS	0.00	0/69	5.19	7/135	0.0979
CAL-R	CNA	0	0/69	2.21	3/136	0.5523

NGS, next-generation sequencing; IHC, immunohistochemistry; MSI, microsatellite instability; FA, fragment analysis; TMB, tumor mutational burden; CNA, copy number alteration; EGFR, epidermal growth factor receptor; CISH, chromogenic in situ hybridization; DDR, DNA damage response; MMR, mismatch repair.